Partners Founding • Funding Assets • Innovation

Joshua P. Fairbank

Mr. Fairbank leads the investment and finance team at Orchard. He is the cofounder of several healthcare and medical companies.

He is a co-founder and original director of Akebia Therapeutics (NASDAQ: AKBA). Founding Akebia he played a key role in all aspects from writing the business plan and hiring management to negotiating the acquisition of the assets from Procter & Gamble. Akebia raised $100 million in venture funding and another $100 million from its IPO. The company has advanced from early animal data to late stage human trials.

Founding Nymirum he built and implemented a non-dilutive business and financing model to enable the development of a novel drug discovery technology. He served as president and chairman at Nymirum, overseeing operations, finance, and business development as well as directing the computational component of the company's platform.

He actively works with the boards of other Orchard portfolio companies.

Prior to working in venture capital Fairbank spent a decade in investment banking and asset management. He began his financial career at Frank Russell, one of the original major fund of funds and fund advisors. He later founded an investment office at Raymond James that focused on private placements and working with large family investors.

J.P. received his MBA from the University of Chicago Booth School of Business and his bachelor's degree from Connecticut College with a double major in Economics and Government.

Michael E. Pape

A 25-year veteran of large pharmaceutical and startup life science companies, Dr Pape engages with portfolio companies in different capacities ranging from board director to scientific director.

At Upjohn and Parke-Davis/Warner-Lambert (now Pfizer) he was instrumental in the success of numerous cardiovascular drug discovery and development programs including Lipitor. Since Lipitor Mike has found similar success as an entrepreneur. In 1998 he co-founded Esperion Therapeutics. He held a variety of executive positions and was involved in nearly all aspects of building Esperion, from its startup to its acquisition by Pfizer for $1.3 billion in 2004. At Nymirum he again served in a broad capacity as CEO and CSO while as a co-founder of Akebia served as a board director and drug development advisor.

He has served as a board member of MichBio the state-wide organization promoting life sciences. He has also been an advisor or investor in numerous medical startup companies. He currently serves on the External Advisory Board for the Purdue Research Foundation Emerging Innovations Fund.

In addition to his company efforts, Mike lectures in a variety of biochemistry courses at the University of Michigan and has published dozens of biochemistry articles describing gene expression and drug activities in heart disease, diabetes, and obesity. Mike’s entrepreneurial achievements have led to his inclusion in the book How They Did It: Billion Dollar Insights from the Heart of America and being named recipient of the 2012 Distinguished Alumni Award in Entrepreneurship from the University of Chicago Booth School of Business.

Mike received his bachelor's degree in Microbiology from the University of Michigan, Ph.D. in Biochemistry from Purdue University, and MBA from the University of Chicago, Booth School of Business.

Board of Advisors

Michael Marletta, PhD
President & CEO, Scripps


Dr. Marletta is a renowned biochemist who has worked at several of the county's top research universities, including MIT, U Michigan, and most recently UC Berkeley where he served as chair and distinguished professor of the Department of Chemistry. He has been awarded the MacArthur "Genius" Award and numerous other awards and honors. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Marletta is widely published and serves on the editorial boards of several scientific journals.

www.scripps.edu/research/faculty/marletta

Brian Moldover, PhD
President B-Tech

Former Head of Global Research Computing at Shering, US Head of Bioinformatics at Aventis, Associate Director of Bioinformatics at Warner-Lambert. Current President of B-Tech which provides outsourced CRO services for bioinformatics, clinical informatics, and genomics.

Edward Pagani, PhD
CEO LGC North America
Former Head of Strategic Alliances of Pfizer Global R&D, Ann Arbor


Currently CEO North America at LGC Ltd. Prior to his current position Dr. Pagani served as Vice President and General Manager of Beckman Coulter Molecular Diagnostics. A long-time executive and scientist in the healthcare industry, Dr. Pagani previously served as Senior Director and Head of Strategic Alliances, Pfizer Global R&D, Ann Arbor MI.

LGC - Pagani

Kalyan Handique, PhD
CEO DeNovo Sciences, Founder HandyLabs


"Handy" Handique founded HandyLab, a molecular diagnostic company, in 2000 while earning his Ph.D. in microfluidics at the University of Michigan. HandyLab was acquired by Becton Dickinson (BD) Diagnostic Systems for $275 Million. He then served as VP of R&D Systems Development for BD Diagnostics. He is currently the CEO of DeNovo Sciences, a cancer diagnostics start-up.

Uday Saxena, PhD
Former CEO Reddy US Therapeutics, former CSO Dr. Reddy's Laboratory


Oversaw global R&D at Dr. Reddy's, the largest pharmaceutical company in India. Prior to Reddy's he held leadership positions at Park-Davis and AtheroGenics. Elected fellow of the Council on Arteriosclerosis, American Heart Association. He is currently co-founder and Chief Advisor R&D at Kareus Therapeutics.

Jennifer Doudna, PhD
Professor of Biochemistry, Biophysics and Structural Biology, UC Berkeley


Member Howard Hughes Medical Institute, National Academy of Sciences, Institute of Medicine. Former Henry Ford II Professor of Molecular Biophysics and Biochemistry at Yale. Former Research Fellow in Genetics, Harvard Medical School. Has served as consultant and/or collaborator to Pfizer, Merck, and Gilead.

Berkeley Faculty, Doudna

Steve Sensoli
Executive Director of Global BD, Banner Pharmacaps

Former Managing Director of China Operations at Leeco Diagnostics and head of Leeco's contract manufacturing operations for Johnson & Johnson. Former co-founder and CEO of GeneWorks. Former President and COO of GlyDerm.

Peter Lankau
Executive Chairman of the Board, Nautilus Neurosciences

Former CEO of Endo Pharmaceuticals (NASDAQ: ENDO), former CEO of Logical Therapeutics, former VP Sales and Marketing at Alpharma.